Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2021-02-11 5:14 pm Purchase | 13G | CRISPR THERAPEUTICS AG NAMEN A CRSP | Nikko Asset Management Americas Inc. | 3,836,823 5.39% | 787,270 (+25.82%) | View |
| 2021-02-05 06:10 am Purchase | 13G | CRISPR THERAPEUTICS AG NAMEN A CRSP | Sumitomo Mitsui Trust Holdings Inc. | 3,836,823 5.39% | 786,938 (+25.80%) | View |
| 2020-10-09 1:51 pm Purchase | 13G | CRISPR THERAPEUTICS AG NAMEN A CRSP | ARK Investment Management LLC | 8,457,320 12.05% | 8,457,320 (New Position) | View |
| 2020-09-18 5:05 pm Sale | 13D | CRISPR THERAPEUTICS AG NAMEN A CRSP | Versant Venture Capital IV L.P. | 2,087,120 3% | -165,136 (-7.33%) | View |
| 2020-09-11 11:04 am Unchanged | 13G | CRISPR THERAPEUTICS AG NAMEN A CRSP | Capital International Investors | 7,519,803 10.7% | 0 (Unchanged) | View |
| 2020-09-10 2:54 pm Purchase | 13G | CRISPR THERAPEUTICS AG NAMEN A CRSP | Capital International Investors | 7,519,803 10.7% | 7,519,803 (New Position) | View |
| 2020-07-10 5:26 pm Purchase | 13D | CRISPR THERAPEUTICS AG NAMEN A CRSP | GSK plc GSK | 3,310,627 4.8% | 15,000 (+0.46%) | View |
| 2020-02-14 4:09 pm Purchase | 13D | CRISPR THERAPEUTICS AG NAMEN A CRSP | GSK plc GSK | 3,295,627 5.5% | 30,000 (+0.92%) | View |
| 2020-02-13 4:05 pm Sale | 13G | CRISPR THERAPEUTICS AG NAMEN A CRSP | VERTEX PHARMACEUTICALS INC VRTX | 2,690,470 4.4% | -2,690,470 (-50.00%) | View |
| 2020-02-12 3:19 pm Purchase | 13G | CRISPR THERAPEUTICS AG NAMEN A CRSP | Nikko Asset Management Americas Inc. | 3,049,553 5.08% | 3,049,553 (New Position) | View |
| 2020-02-12 06:02 am Purchase | 13G | CRISPR THERAPEUTICS AG NAMEN A CRSP | Sumitomo Mitsui Trust Holdings Inc. | 3,049,885 5.08% | 3,049,885 (New Position) | View |
| 2020-02-04 4:19 pm Sale | 13D | CRISPR THERAPEUTICS AG NAMEN A CRSP | Bayer Global Investments B.V. | 2,954,775 4.9% | -732,837 (-19.87%) | View |
| 2020-01-24 4:09 pm Sale | 13D | CRISPR THERAPEUTICS AG NAMEN A CRSP | Bayer Global Investments B.V. | 3,687,612 6.1% | -632,105 (-14.63%) | View |
| 2020-01-10 4:49 pm Sale | 13D | CRISPR THERAPEUTICS AG NAMEN A CRSP | Bayer Global Investments B.V. | 4,319,717 7.2% | -785,613 (-15.39%) | View |
| 2019-11-26 4:30 pm Unchanged | 13G | CRISPR THERAPEUTICS AG NAMEN A CRSP | VERTEX PHARMACEUTICALS INC VRTX | 5,380,940 9.1% | 0 (Unchanged) | View |
| 2019-06-28 2:28 pm Sale | 13D | CRISPR THERAPEUTICS AG NAMEN A CRSP | Versant Venture Capital IV L.P. | 2,252,256 4.3% | -500,000 (-18.17%) | View |
| 2019-06-07 4:04 pm Unchanged | 13D | CRISPR THERAPEUTICS AG NAMEN A CRSP | VERTEX PHARMACEUTICALS INC VRTX | 5,380,940 10.2% | 0 (Unchanged) | View |